News and Announcements
Moscar Capital announces investment into Diamond White Aligners
- Published February 24, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Moscar Capital are delighted to announce our investment into Diamond White Aligners (DWA). The company offers a cost-effective alternative to braces for straightening your teeth, with savings of up to 70%. DWA director, Richard Marques, is one of the highest-profile dentists in the UK with many celebrity clients, including Rita Ora and Dua Lipa, and the exposure and PR Richard receives helps explain the company’s stratospheric growth.
Despite DWA only starting to trade in June 2020 the company is already profitable. Their first year’s revenue is set to exceed £2m and they enjoy a run-rate of over £3m. Moscar Capital’s investment and expertise will support DWA’s continued growth in the UK, as well as supporting their expansion into new territories, including Australia.
With the worldwide invisible aligner market set to increase by 18% YoY until 2026 we feel it is a fantastic time to invest in DWA, and we are sure they have the right team to ensure the enterprise is a huge success.
To learn more about DWA and Moscar Capital email [email protected].
About Moscar Capital
Moscar is a venture capital fund managed from London who target smaller bootstrapped companies with valuations ranging from £2m-£10m. The growth in these companies has been harnessed by their ambitious founders, who share our unstoppable drive to build compelling financial and societal returns. We target revenue generating companies with minimal cash burn to ensure that these are viable businesses with market demand. Our investment is then used for growth capital with easily monitored objectives.
Post investment, we prepare our companies for institutional funding by producing a clear road map to a larger Series-A round, ideally within 12-18 months. We assist with board formulation, business analysis and modelling for expansion, making the company attractive for institutional investors. With our hands-on approach we don’t just invest in businesses – we become deeply invested in them.
The Fund is targeting an internal rate of return (“IRR”) of 25% per annum, or 5x cash on cash, over a maximum 7-year period.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
